Unknown

Dataset Information

0

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.


ABSTRACT: We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.

SUBMITTER: Ohnuma K 

PROVIDER: S-EPMC3838260 | biostudies-other | 2013 Dec

REPOSITORIES: biostudies-other

altmetric image

Publications

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.

Ohnuma Kei K   Haagmans Bart L BL   Hatano Ryo R   Raj V Stalin VS   Mou Huihui H   Iwata Satoshi S   Dang Nam H NH   Bosch Berend Jan BJ   Morimoto Chikao C  

Journal of virology 20130925 24


We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV infection. YS110, in particular, is a good candidate for immediate testing as a therape  ...[more]

Similar Datasets

2014-06-10 | E-GEOD-55023 | biostudies-arrayexpress
| S-EPMC5324816 | biostudies-literature
| S-EPMC6986839 | biostudies-literature